CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+1.13%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+17%)
Cap. Flow
+$170M
Cap. Flow
% of AUM
15.9%
Top 10 Holdings %
Top 10 Hldgs %
64.66%
Holding
34
New
5
Increased
13
Reduced
3
Closed
3
Top Buys
| 1 |
Codexis
CDXS
|
$52M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
$38.5M |
| 3 |
Adaptive Biotechnologies
ADPT
|
$20.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$14.9M |
| 5 |
Twist Bioscience
TWST
|
$8.7M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$9.24M |
| 2 |
Evolent Health
EVH
|
$6.92M |
| 3 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$5.65M |
| 4 |
Gilead Sciences
GILD
|
$5.2M |
| 5 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$1.7M |
Sector Composition
| 1 | Healthcare | 81.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $90.6M | 8.48% | 884,800 -55,200 | -6% | -$5.65M |
|
|
NVTA
2
DELISTED
Invitae Corporation
NVTA
| $90.2M | 8.44% | 3,838,388 +1,638,388 | +74% | +$38.5M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $88.7M | 8.3% | 940,000 +91,352 | +11% | +$8.62M |
|
|
4
Codexis
CDXS
$246M
| $86.5M | 8.1% | 5,073,780 +3,048,780 | +151% | +$52M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $73.2M | 6.85% | 400,000 | – | – |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $64.4M | 6.03% | 1,285,000 | – | – |
|
7
Fate Therapeutics
FATE
$120M
| $51.8M | 4.85% | 2,550,000 | – | – |
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $50.9M | 4.76% | 335,000 +30,000 | +10% | +$4.56M |
|
|
BLUE
9
DELISTED
bluebird bio
BLUE
| $47.4M | 4.43% | 372,500 +15,000 | +4% | +$1.91M |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $47.2M | 4.41% | 650,000 +205,000 | +46% | +$14.9M |
|
11
Dianthus Therapeutics
DNTH
$759M
| $44.3M | 4.15% | 3,003,121 +359,803 | +14% | +$5.31M |
|
12
BioLife Solutions
BLFS
$1.2B
| $39.4M | 3.69% | 2,428,571 | – | – |
|
|
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
| $36.5M | 3.42% | 965,000 -45,000 | -4% | -$1.7M |
|
14
Voyager Therapeutics
VYGR
$186M
| $30.7M | 2.87% | 1,128,075 | – | – |
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $24.7M | 2.31% | 495,000 +160,000 | +48% | +$7.98M |
|
16
Illumina
ILMN
$15.8B
| $22.1M | 2.07% | 60,000 | – | – |
|
|
GNMK
17
DELISTED
GenMark Diagnostics, Inc
GNMK
| $21.8M | 2.04% | 3,365,000 | – | – |
|
|
18
Adaptive Biotechnologies
ADPT
$2.01B
| $20.1M | 1.88% | +463,125 | New | +$20.1M |
|
|
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $19.7M | 1.85% | 1,770,000 +649,414 | +58% | +$7.23M |
|
|
CNST
20
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $18.7M | 1.75% | 1,523,960 -33,039 | -2% | -$406K |
|
21
Sangamo Therapeutics
SGMO
$157M
| $16.5M | 1.54% | 1,530,000 +450,000 | +42% | +$4.85M |
|
|
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.8M | 1.48% | 300,000 | – | – |
|
23
Q32 Bio
QTTB
$20.9M
| $14.6M | 1.36% | 745,000 +395,000 | +113% | +$7.73M |
|
24
Editas Medicine
EDIT
$231M
| $11.9M | 1.11% | 480,000 | – | – |
|
25
Alector
ALEC
$238M
| $10.2M | 0.95% | 551,039 +220,000 | +66% | +$4.07M |
|